DK1073456T3 - Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme - Google Patents
Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdommeInfo
- Publication number
- DK1073456T3 DK1073456T3 DK99918766T DK99918766T DK1073456T3 DK 1073456 T3 DK1073456 T3 DK 1073456T3 DK 99918766 T DK99918766 T DK 99918766T DK 99918766 T DK99918766 T DK 99918766T DK 1073456 T3 DK1073456 T3 DK 1073456T3
- Authority
- DK
- Denmark
- Prior art keywords
- osteoprotegerin
- prevention
- treatment
- cardiovascular diseases
- opg
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 3
- 102000008108 Osteoprotegerin Human genes 0.000 title abstract 3
- 108010035042 Osteoprotegerin Proteins 0.000 title abstract 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/064,832 US6790823B1 (en) | 1998-04-23 | 1998-04-23 | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| PCT/US1999/008793 WO1999053942A1 (en) | 1998-04-23 | 1999-04-21 | Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1073456T3 true DK1073456T3 (da) | 2005-10-24 |
Family
ID=22058524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99918766T DK1073456T3 (da) | 1998-04-23 | 1999-04-21 | Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6790823B1 (https=) |
| EP (1) | EP1073456B1 (https=) |
| JP (1) | JP4776774B2 (https=) |
| AT (1) | ATE303817T1 (https=) |
| AU (1) | AU757806B2 (https=) |
| CA (1) | CA2325360C (https=) |
| DE (1) | DE69927147T2 (https=) |
| DK (1) | DK1073456T3 (https=) |
| ES (1) | ES2248998T3 (https=) |
| SI (1) | SI1073456T1 (https=) |
| WO (1) | WO1999053942A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| DE69740107D1 (de) | 1996-12-23 | 2011-03-10 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| ES2263204T5 (es) | 1997-04-15 | 2013-10-14 | Daiichi Sankyo Company, Limited | Nueva proteína y proceso para producir la misma |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| ES2284203T5 (es) | 1997-04-16 | 2016-03-11 | Amgen Inc. | Proteínas de unión a osteoprotegerina y sus receptores |
| JP4380067B2 (ja) * | 1998-04-23 | 2009-12-09 | 味の素株式会社 | 抗血栓活性物質及びグリコカリシンの検出法 |
| AU762574B2 (en) | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
| EP1377610A2 (en) * | 2001-04-03 | 2004-01-07 | Société des Produits Nestlé S.A. | Osteoprotegerin in milk |
| US7198798B2 (en) * | 2001-05-10 | 2007-04-03 | University Of Washington | Methods and devices for promoting endothelial morphogenesis |
| US7064189B2 (en) | 2001-05-25 | 2006-06-20 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US8649843B2 (en) * | 2001-11-24 | 2014-02-11 | Ben A. Arnold | Automated calcium scoring of the aorta |
| US7718776B2 (en) | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| EP1515743A2 (en) * | 2002-04-10 | 2005-03-23 | Applied Research Systems ARS Holding N.V. | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| US7612153B2 (en) | 2004-10-25 | 2009-11-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) and uses thereof |
| US7601796B2 (en) | 2005-01-04 | 2009-10-13 | Intezyne Technologies, Inc. | Synthesis of hybrid block copolymers and uses thereof |
| US7561727B2 (en) * | 2005-06-02 | 2009-07-14 | Nordic Bioscience Imaging A/S | Method of deriving a quantitative measure of a degree of calcification of an aorta |
| US7463758B2 (en) * | 2005-06-02 | 2008-12-09 | Nordio Bioscience A/S | Method of deriving a quantitative measure of a degree of calcification of an aorta |
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
| FR2970870A1 (fr) * | 2011-01-31 | 2012-08-03 | Centre Nat Rech Scient | Modulation de la proliferation des cellules epitheliales de l'unite epidermo-pilo-sebacee via rank |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
-
1998
- 1998-04-23 US US09/064,832 patent/US6790823B1/en not_active Expired - Fee Related
-
1999
- 1999-04-21 JP JP2000544345A patent/JP4776774B2/ja not_active Expired - Fee Related
- 1999-04-21 WO PCT/US1999/008793 patent/WO1999053942A1/en not_active Ceased
- 1999-04-21 DK DK99918766T patent/DK1073456T3/da active
- 1999-04-21 EP EP99918766A patent/EP1073456B1/en not_active Expired - Lifetime
- 1999-04-21 ES ES99918766T patent/ES2248998T3/es not_active Expired - Lifetime
- 1999-04-21 CA CA002325360A patent/CA2325360C/en not_active Expired - Fee Related
- 1999-04-21 SI SI9930826T patent/SI1073456T1/sl unknown
- 1999-04-21 DE DE69927147T patent/DE69927147T2/de not_active Expired - Lifetime
- 1999-04-21 AT AT99918766T patent/ATE303817T1/de active
- 1999-04-21 AU AU36605/99A patent/AU757806B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999053942A1 (en) | 1999-10-28 |
| US6790823B1 (en) | 2004-09-14 |
| ATE303817T1 (de) | 2005-09-15 |
| CA2325360C (en) | 2008-11-04 |
| AU3660599A (en) | 1999-11-08 |
| JP4776774B2 (ja) | 2011-09-21 |
| DE69927147D1 (de) | 2005-10-13 |
| WO1999053942A8 (en) | 1999-12-02 |
| CA2325360A1 (en) | 1999-10-28 |
| AU757806B2 (en) | 2003-03-06 |
| JP2002512199A (ja) | 2002-04-23 |
| ES2248998T3 (es) | 2006-03-16 |
| SI1073456T1 (sl) | 2005-12-31 |
| DE69927147T2 (de) | 2006-01-26 |
| EP1073456A1 (en) | 2001-02-07 |
| EP1073456B1 (en) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1073456T3 (da) | Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme | |
| NO993979L (no) | FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor | |
| DK0959888T3 (da) | Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom | |
| ATE376832T1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
| DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
| IL245956A0 (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
| BR9908438A (pt) | Tabletes de desintegração rápida | |
| MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
| EP1631269A4 (en) | METHOD AND COMPOSITIONS FOR DISTRIBUTING CATECHOLIC BUTANESE FOR THE TREATMENT OF ADIPOSITAS | |
| DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
| BR0313148A (pt) | Formulações de liberação controlada compreendendo lamotrigina | |
| DK0998287T3 (da) | Anvendelse af levobupivacain | |
| CY1114133T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ | |
| ATE272628T1 (de) | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen | |
| IL164217A0 (en) | Pharmaceutical compositions containing water-soluble propofol and methods of administering same | |
| NO20004419L (no) | Ny anvendelse | |
| DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
| DK1007040T3 (da) | Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom | |
| AU2001257406A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
| GB9907571D0 (en) | Compounds | |
| WO2002064160A3 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DK0787135T3 (da) | Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh | |
| SE0001916D0 (sv) | Novel formulation | |
| DE60025215D1 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit |